Mirati Therapeutics, Inc (MRTX)

Etorro trading 970x250
Mirati Therapeutics, Inc (MRTX) Logo

About Mirati Therapeutics, Inc

Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase I/II clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; and Sitravatinib, an investigational spectrum-selective kinase inhibitor that is in Phase II clinical trial for the treatment of NSCL cancer, as well as a KRAS G12D inhibitor program, which is in preclinical development. It has a collaboration and license agreement with BeiGene, Ltd. to develop, manufacture, and commercialize sitravatinib; and a clinical collaboration agreement with Novartis Pharmaceuticals Corporation. Mirati Therapeutics, Inc. was founded in 1995 and is headquartered in San Diego, California. Address: 9393 Towne Centre Drive, San Diego, CA, United States, 92121

Mirati Therapeutics, Inc News and around…

Latest news about Mirati Therapeutics, Inc (MRTX) common stock and company :

MRTX Crosses Above Key Moving Average Level
12 Oct, 2021 FinancialContent

In trading on Tuesday, shares of Mirati Therapeutics Inc (MRTX) crossed above their 200 day moving average of $173.90, changing hands as high as $177.71 per share. Mirati Therapeutics Inc shares are currently trading up about 2.5% on the day..

Notable ETF Outflow Detected - PDP, DPZ, CELH, MRTX
12 Oct, 2021 FinancialContent

Symbols mentioned in this story: PDP, DPZ, CELH, MRTX Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand..

The Daily Biotech Pulse: Allogene Sinks On FDA Clinical Hold, Takeda Gets Adcom Backing, Quidel Reports Q3 COVID Revenues, IPOs
08 Oct, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

Mirati Therapeutics to Collaborate with Sanofi on Phase 1/2 Study Evaluating Combination of adagrasib with a SHP2 Inhibitor in KRAS G12C-mutated Lung Cancer
07 Oct, 2021 Yahoo! Finance

Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced a non-exclusive clinical collaboration agreement with Sanofi to evaluate the combination of adagrasib, the Company's investigational KRASG12C inhibitor, with Sanofi's investigational SHP2 inhibitor SAR442720, also known as RMC-4630. The Phase 1/2 dose escalation and expansion study will evaluate the combination in patients with previously-treated non-small cell lung cancer (NSCLC) and KRASG12C m

Merck Keeps M&A Mode On With Mirati, Biogen, mRNA Companies On Radar: FT
06 Oct, 2021 FinancialContent

Merck & Co Inc(NYSE: MRK) remains in a deal-hunting mode despite its recent $11.5 billion acquisition of ...

Mirati Therapeutics to Present New Research From its Innovative Oncology Pipeline at the 2021 AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer
04 Oct, 2021 Yahoo! Finance

Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced new clinical and preclinical research will be presented at the 2021 AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics, taking place October 7 - 10, 2021.

Hedge Funds Are Selling Mirati Therapeutics, Inc. (MRTX)
04 Oct, 2021 Yahoo! Finance

Hedge funds and large money managers usually invest with a focus on the long-term horizon and, therefore, short-lived dips or bumps on the charts usually don’t make them change their opinion towards a company. This time it may be different. The coronavirus pandemic destroyed the high correlations among major industries and asset classes. We are […]

Mirati Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
24 Sep, 2021 Yahoo! Finance

Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced that in connection with the hiring, announced on September 20, 2021, of David Meek as Chief Executive Officer, Mr. Meek received an inducement award to purchase up to 150,300 shares of common stock. The stock option has an exercise price per share of $167.10, the closing price of the Company's common stock on the Nasdaq Global Select Market on September 22, 2021 and will vest over four years, wi

What 6 Analyst Ratings Have To Say About Mirati Therapeutics
23 Sep, 2021 FinancialContent

Over the past 3 months, 6 analysts have published their opinion on Mirati Therapeutics (NASDAQ:MRTX) stock. These analysts are ...

Benzinga's Top Ratings Upgrades, Downgrades For September 23, 2021
23 Sep, 2021 FinancialContent

Upgrades Barclays upgraded the previous rating for Warner Music Group Corp (NASDAQ:WMG) from Equal-Weight to Overweight. ...

9 Health Care Stocks Showing Unusual Options Activity In Today's Session
21 Sep, 2021 FinancialContent

This unusual options alert can help traders discover the next big trading opportunities. Traders will search for circumstances when the ...

Expert Ratings For Mirati Therapeutics
21 Sep, 2021 FinancialContent

Over the past 3 months, 5 analysts have published their opinion on Mirati Therapeutics (NASDAQ:MRTX) stock. These analysts are typically ...

10 Biggest Price Target Changes For Tuesday
21 Sep, 2021 FinancialContent

RBC Capital boosted MSCI Inc. (NYSE: MSCI) price target from $650 to $720. MSCI shares rose 1.6% to $645.00 in pre-market ...

Why Mirati Therapeutics Is A Dangerous Rival To Amgen In Colon Cancer
20 Sep, 2021 FinancialContent

Mirati could beat Amgen to market with a KRAS-blocking colon cancer drug, an analyst said Monday as MRTX stock rocketed.

Why Mirati Therapeutics Stock Is Trading Higher Today
20 Sep, 2021 FinancialContent

Mirati Therapeutics Inc (NASDAQ: MRTX) is trading higher Monday afterthe company announced clinical data with investigational ...

35 Stocks Moving In Monday's Mid-Day Session
20 Sep, 2021 FinancialContent

Gainers ZIVO Bioscience, Inc. (NASDAQ: ZIVO) jumped 145% to $6.86 after declining around 17% on Friday. Edesa Biotech, Inc. ...

Mirati (MRTX) Reports Positive Data From Colorectal Cancer Study
20 Sep, 2021 Yahoo! Finance

Mirati (MRTX) reports positive data from a cohort of the phase I/IIstudy evaluating its KRAS inhibitor adagrasib in patients with KRAS G12C-mutated colorectal cancer.

New CEO At Mirati Therapeutics
20 Sep, 2021 FinancialContent

Amid data readouts from adagrasib, sitravatinib programs,Mirati Therapeutics Inc(NASDAQ: MRTX)has ...

Mirati Unveils Long-term Survival Data For Sitravatinib/Nivolumab Combo In Lung Cancer Patients
20 Sep, 2021 FinancialContent

Mirati Therapeutics Inc(NASDAQ: MRTX) hasannounced results from a post hoc exploratory analysisof the Phase 2 ...

Mirati Posts Adagrasib Data In KRAS-Mutated Lung Cancer, FDA Filing Now On The Cards
20 Sep, 2021 FinancialContent

Afterdata readout from KRAS drug adagrasib in colon cancer,Mirati Therapeutics Inc(NASDAQ: MRTX) hasannounced ...

Mirati Showcases New KRAS Drug Data In Colorectal Cancer At ESMO
20 Sep, 2021 FinancialContent

Mirati Therapeutics Inc(NASDAQ: MRTX)announced results from the 600mg BID dose cohortof the Phase 1/2 ...

Mirati Therapeutics Announces Long-term Survival Results from an Exploratory Analysis of Sitravatinib plus Nivolumab in Patients with Non-squamous Non-Small Cell Lung Cancer Who are Resistant to Checkpoint Inhibitors
20 Sep, 2021 Yahoo! Finance

Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced results from a post hoc exploratory analysis of the Phase 2 study, MRTX-500. Results showed durable responses and long-term survival with sitravatinib in combination with nivolumab (OPDIVO®)1 in patients with second or third line non-squamous non-small cell lung cancer (NSCLC) who experienced clinical benefit on a prior checkpoint inhibitor (CPI) and subsequent disease progression (n=68).

Mirati Therapeutics taps industry veteran Meek as CEO
20 Sep, 2021 Yahoo! Finance

Mirati Therapeutics Inc named industry veteran David Meek as its chief executive officer on Monday as it pushes on with the development of its promising candidates for cancer treatment. 58-year-old Meek will join the company's board and replaces Charles Baum, who has served as the president and CEO of California-based Mirati since 2012. Meek most recently headed gene-therapy company FerGene, which was launched in 2019 by Swiss drugmaker Ferring Pharmaceuticals and investment firm Blackstone Life Sciences.

Mirati Therapeutics Appoints David Meek as Chief Executive Officer
20 Sep, 2021 Yahoo! Finance

Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced the appointment of David Meek as Chief Executive Officer (CEO), effective immediately. Mr. Meek will also join the Company's Board of Directors. Charles M. Baum, M.D., Ph.D. will continue to lead the research and development (R&D) organization as president, founder and head of R&D. Dr. Baum will remain on the Company's Board of Directors.

Mirati Therapeutics Announces Positive Phase 2 Topline Results for Investigational Adagrasib in Patients with KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer
20 Sep, 2021 Yahoo! Finance

Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced positive topline results from the potentially registration-enabling cohort of the Phase 2 KRYSTAL-1 study, evaluating adagrasib in patients with advanced non-small cell lung cancer (NSCLC) harboring the KRASG12C mutation following prior systemic therapy.

Mirati Therapeutics Presents Positive Clinical Data with Investigational Adagrasib as Monotherapy and in Combination with Cetuximab in Patients with KRAS G12C-Mutated Colorectal Cancer
19 Sep, 2021 Yahoo! Finance

Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced results from a cohort of the Phase 1/2 KRYSTAL–1 study evaluating adagrasib at the 600mg BID dose as both monotherapy and in combination with cetuximab in patients with heavily pretreated colorectal cancer harboring a KRASG12C mutation. Results showed that adagrasib alone and with cetuximab demonstrated significant clinical activity and broad disease control in these patients. The findings (Abst

Mirati drug combination shrinks tumors in 39% of colon cancer patients in study
19 Sep, 2021 Yahoo! Finance

A combination of Mirati Therapeutics Inc's genetic mutation-targeting adagrasib and older cancer drug Erbitux shrank tumors in 39% of patients with advanced colorectal cancer treated in a small trial, the company said on Sunday. Chief Executive Officer Charles Baum told Reuters Mirati plans to meet with the U.S. Food and Drug Administration in October to discuss whether it can pursue accelerated approval based on the combination therapy data. Adagrasib targets a mutated form of a gene known as KRAS that occurs in around 13% of non-small cell lung cancers, 3% to 5% of colorectal cancers and up to 2% of other solid tumor cancers.

The Week Ahead In Biotech (Sept. 19-25): Incyte, Verrica FDA Decisions And Conference Presentations In The Spotlight
19 Sep, 2021 FinancialContent

Biotech stocks declined for the week endingSept. 17, extending the losses from the previous week. European Society for Medical ...

Noteworthy Thursday Option Activity: PACB, DASH, MRTX
16 Sep, 2021 FinancialContent

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Pacific Biosciences of California Inc (PACB), where a total volume of 30,151 contracts has been traded thus far today, a contract volume which is representative of approximately 3.0 million underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 193.5% of PACB's average daily trading volume over the past month, of 1.6 million shares..

Mirati Therapeutics to Host Virtual Investor Event on Monday, September 20, 2021
15 Sep, 2021 Yahoo! Finance

Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced that the Company will host a virtual Investor Event on Monday, September 20, 2021 at 8:30 a.m. ET / 5:30 a.m. PT.

Mirati Therapeutics, Inc (MRTX) is a NASDAQ Common Stock listed in , ,

970x250